Form 8-K
Material Company Update
2026-07-29
JNJ filed 8-K — material company event
JOHNSON & JOHNSON filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
Latest SEC filings for Johnson & Johnson (JNJ) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). All data sourced directly from SEC EDGAR — last updated 2026-07-29.
JOHNSON & JOHNSON filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
JOHNSON & JOHNSON filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
JOHNSON & JOHNSON filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.
Broadhurst Vanessa, listed as EVP, Global Corp Affairs at JOHNSON & JOHNSON, reported an open-market sale of 23,054 JNJ shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Broadhurst Vanessa filed a Form 144 with the SEC indicating intent to sell JNJ (JOHNSON & JOHNSON) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.
JOHNSON & JOHNSON filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
Wengel Kathryn E, listed as EVP, Chief TO and Risk Officer at JOHNSON & JOHNSON, reported an open-market sale of 10,000 JNJ shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Woods Eugene A. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Pinto Daniel E (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
HEWSON MARILLYN A (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Wengel Kathryn E filed a Form 144 with the SEC indicating intent to sell JNJ (JOHNSON & JOHNSON) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
REED JOHN C (EVP, Innovative Medicine, R&D) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
JOHNSON & JOHNSON filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
Woods Eugene A. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
West Nadja (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
WEINBERGER MARK A (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Pinto Daniel E (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
MORIKIS JOHN G (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
McClellan Mark B. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Joly Hubert (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Executives, directors, and large shareholders must report any purchase or sale of JNJ shares within two business days. Consistent buying by multiple insiders is often read as a confidence signal; large sales may reflect diversification or liquidity needs rather than negative conviction.
Filed when a company affiliate intends to sell restricted or control shares. A Form 144 is a notice of intent, not confirmation — the actual sale is later confirmed via Form 4. It gives investors advance visibility into planned insider selling activity.
The 8-K is an event-driven filing that Johnson & Johnson must submit within four business days of a significant development — including earnings results, mergers, executive changes, credit facility updates, or regulatory actions. Each 8-K item code maps to a specific event type.
The 10-Q (quarterly) and 10-K (annual) are comprehensive reports covering Johnson & Johnson's financial results, risk factors, management discussion, and business operations. The 10-K includes audited financials and is the most complete public disclosure the company makes each year.
View valuation, growth metrics, AI Strong Buy score, demand zones, peer comparison, and more — all on the JNJ stock analysis page.